P1.09-01 PD-L1 Testing on NSCLC Cytology Samples in a UK Teaching Hospital

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.777
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.09-03 Challenges in PD-L1 Immunoexpression in Liquid Based Cytology Samples of Advanced Stage Non-Small Cell Lung Carcinomas

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.09-04 Assessment of PD-L1 Expression in Cytology Samples: An Anlaysis of 263 Consecutive NSCLC Biopsies.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.04-16 Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC With High PD-L1 Expression Tested on Cytology Versus Biopsy Samples

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.09-04 Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA19.02 Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.09-06 the Incidence of PD-L1 in NSCLC and Its Correlation With Driver Mutations in Turkish Patients; A Single Center Experience

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

45. A Retrospective Assessment of PD-L1 Expression Rates in NSCLC

Pathology
Forensic MedicinePathology
2020English

PD-L1-Hemmer Bei Vorbehandelten Patienten Mit NSCLC

Im Focus Onkologie
2017English

NSCLC: Zwei Positive Studien Zu PD-L1-Hemmer

Im Focus Onkologie
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy